Molecular Partners (MOLN) Revenue & Revenue Breakdown
Molecular Partners Revenue Highlights
Latest Revenue (Y)
$7.04M
Latest Revenue (Q)
$2.74M
Main Geography (Y)
SWITZERLAND
Molecular Partners Revenue by Period
Molecular Partners Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $7.04M | -96.29% |
| 2022-12-31 | $189.56M | 1931.68% |
| 2021-12-31 | $9.33M | -0.15% |
| 2020-12-31 | $9.34M | -54.16% |
| 2019-12-31 | $20.38M | 96.84% |
| 2018-12-31 | $10.36M | -48.27% |
| 2017-12-31 | $20.02M | -13.13% |
| 2016-12-31 | $23.04M | -20.88% |
| 2015-12-31 | $29.12M | 9.37% |
| 2014-12-31 | $26.63M | -17.87% |
| 2013-12-31 | $32.42M | - |
Molecular Partners generated $7.04M in revenue during NA 2023, up -96.29% compared to the previous quarter, and up 67.97% compared to the same period a year ago.
Molecular Partners Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $2.74M | 165.31% |
| 2023-12-31 | $1.03M | -59.39% |
| 2023-09-30 | $2.54M | 512.29% |
| 2023-06-30 | $415.00K | -86.39% |
| 2023-03-31 | $3.05M | 13.26% |
| 2022-12-31 | $2.69M | 15.23% |
| 2022-09-30 | $2.34M | -80.11% |
| 2022-06-30 | $11.75M | -93.20% |
| 2022-03-31 | $172.78M | 9633.97% |
| 2021-12-31 | $1.77M | -49.67% |
| 2021-09-30 | $3.53M | 9.77% |
| 2021-06-30 | $3.21M | 294.23% |
| 2021-03-31 | $815.00K | -47.25% |
| 2020-12-31 | $1.54M | 445.94% |
| 2020-09-30 | $283.00K | -87.89% |
| 2020-06-30 | $2.34M | - |
| 2020-03-31 | $2.34M | -54.16% |
| 2019-12-31 | $5.10M | - |
| 2019-09-30 | $5.10M | - |
| 2019-06-30 | $5.10M | - |
| 2019-03-31 | $5.10M | 96.84% |
| 2018-12-31 | $2.59M | - |
| 2018-09-30 | $2.59M | - |
| 2018-06-30 | $2.59M | - |
| 2018-03-31 | $2.59M | -48.27% |
| 2017-12-31 | $5.00M | - |
| 2017-09-30 | $5.00M | - |
| 2017-06-30 | $5.00M | - |
| 2017-03-31 | $5.00M | -13.13% |
| 2016-12-31 | $5.76M | - |
| 2016-09-30 | $5.76M | - |
| 2016-06-30 | $5.76M | - |
| 2016-03-31 | $5.76M | -20.88% |
| 2015-12-31 | $7.28M | - |
| 2015-09-30 | $7.28M | - |
| 2015-06-30 | $7.28M | - |
| 2015-03-31 | $7.28M | 9.37% |
| 2014-12-31 | $6.66M | - |
| 2014-09-30 | $6.66M | - |
| 2014-06-30 | $6.66M | - |
| 2014-03-31 | $6.66M | -17.87% |
| 2013-12-31 | $8.10M | - |
| 2013-09-30 | $8.10M | - |
| 2013-06-30 | $8.10M | - |
| 2013-03-31 | $8.10M | - |
Molecular Partners generated $2.74M in revenue during Q1 2024, up 165.31% compared to the previous quarter, and up 101.67% compared to the same period a year ago.
Molecular Partners Revenue Breakdown
Molecular Partners Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| SWITZERLAND | $7.04M | $179.90M | - |
| UNITED STATES | - | $9.65M | $9.33M |
Latest
Molecular Partners's latest annual revenue breakdown by geography, as of Dec 23: SWITZERLAND (100.00%).
Molecular Partners Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TRDA | Entrada Therapeutics | $129.01M | $19.57M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| HCWB | HCW Biologics | $2.84M | $426.42K |
| MNOV | MediciNova | $1.00M | - |
| OPT | Opthea | $108.41K | $61.27K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| RZLT | Rezolute | - | - |
| ANTX | AN2 Therapeutics | - | - |
| PHVS | Pharvaris | - | - |
| RLYB | Rallybio | - | $299.00K |
| CYT | Cyteir Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| VIGL | Vigil Neuroscience | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
| PEPG | PepGen | - | - |
| CSBR | Champions Oncology | - | - |